Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.
Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of patient gender, age, and disease state on levels of soluble HER2 ECD in serum. In addition, these levels were compared to HER2 in tissue. Breast tumor tissue and serum from 565 cancer patients were analyzed before any chemotherapy or radiation. In addition, serum from 283 healthy individuals and serum and breast tissue from 249 patients with a history of breast cancer (had previously undergone chemotherapy and radiation and were cancer free) was also included in the study. Serum was stored frozen at -80 degrees C until assay. Breast tissue was fixed in formalin and embedded in paraffin. For specimens with a DAKO score of 2+, FISH was also performed to determine HER2 status.
Summary of Findings
Serum from healthy men had higher levels of HER2 ECD than serum from healthy women (p<0.001). Among healthy women and those with a previous cancer diagnosis, HER2 ECD levels were higher in serum from older women than from younger women (p<0.001 and p=0.03, respectively), but patient age had no effects on HER2 levels among serum from healthy men. HER2 ECD levels were not compared between serum from healthy females and current breast cancer patients since the median ages for these groups were significantly different (37 y and 58 y, respectively). However, no significant differences were seen in HER2 ECD levels between specimens from current and former breast cancer patients. HER2 positivity in tissue was associated with negative estrogen receptor (ER) and progesterone receptor (PR) status, metastases, large tumor size, lymph node involvement, and high-grade tumors. Multivariate analysis revealed a significant correlation between higher levels of HER2 ECD in serum and postmenopausal status and metastases, while lymph node involvement, tumor grading, and ER/PR status did not show significant correlations with HER2 ECD levels. Regardless of metastases, significantly higher HER2 ECD levels were measured in serum when the corresponding tissue specimens had HER2 immunohistochemistry scores of 3+ rather than 2+, 1+, or 0, but this was only true for the current breast cancer patients who had not undergone treatment, as no correlations were observed between HER2 ECD levels and HER2 immunostaining scores among specimens from previous cancer patients who had been treated.
Biospecimens
TissueBreastFluidSerumFluidBloodPreservation Types
FrozenFormalinDiagnoses
NormalNeoplasticCarcinomaPlatforms
ProteinImmunohistochemistryProteinImmunoassayDNAFISHPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Biomarker level Negative ER statusNegative PR statusPositive ER statusPositive PR statusPreaquisition Diagnosis/ patient condition Current diagnosis of breast cancerNormalPrior diagnosis of breast cancer (remission)Preaquisition Other drugs No prior chemotherapy or radiationPrior chemotherapy and radiationPreaquisition Patient age 35-45 years45-55 years<35 yearsOlder than 55 yearsPostmenopausalPremenopausalPreaquisition Patient gender FemaleMalePreaquisition Prognostic factor Distant metastasesG1 grade tumorG2 grade tumorG3 grade tumorLarge tumor sizeLymph node involvementNo distant metastasesNo lymph node involvementSmall tumor sizeUICC stage IUICC stage IIUICC stage IIIBiospecimen Acquisition Biospecimen location Breast tissueSerum